| Antimicrobial resistance and COVID-19: Intersections and implications GM Knight, RE Glover, CF McQuaid, ID Olaru, K Gallandat, QJ Leclerc, ... Elife 10, e64139, 2021 | 293 | 2021 |
| A framework for identifying and mitigating the equity harms of COVID-19 policy interventions RE Glover, MCI van Schalkwyk, EA Akl, E Kristjannson, T Lotfi, J Petkovic, ... Journal of clinical epidemiology 128, 35-48, 2020 | 178 | 2020 |
| Temporal changes in Ebola transmission in Sierra Leone and implications for control requirements: a real-time modelling study A Camacho, A Kucharski, Y Aki-Sawyerr, MA White, S Flasche, ... PLoS currents 7, 2015 | 147 | 2015 |
| Measuring the impact of Ebola control measures in Sierra Leone AJ Kucharski, A Camacho, S Flasche, RE Glover, WJ Edmunds, S Funk Proceedings of the National Academy of Sciences 112 (46), 14366-14371, 2015 | 126 | 2015 |
| Mathematical modelling for antibiotic resistance control policy: do we know enough? GM Knight, NG Davies, C Colijn, F Coll, T Donker, DR Gifford, RE Glover, ... BMC infectious diseases 19, 1-9, 2019 | 46 | 2019 |
| Vaccinating against covid-19 in people who report allergies RE Glover, R Urquhart, J Lukawska, KG Blumenthal bmj 372, 2021 | 40 | 2021 |
| Impact of a multiplex PCR point-of-care test for influenza A/B and respiratory syncytial virus on an acute pediatric hospital ward AI Vecino-Ortiz, SD Goldenberg, ST Douthwaite, CY Cheng, RE Glover, ... Diagnostic microbiology and infectious disease 91 (4), 331-335, 2018 | 19 | 2018 |
| Subscription model for antibiotic development RE Glover, J Manton, S Willcocks, RA Stabler BMJ 366, 2019 | 17 | 2019 |
| Antibiotic resistance: don¢t blame patients RE Glover, M Dangoor, N Mays BMJ 364, 2019 | 15 | 2019 |
| Methodological guidance for incorporating equity when informing rapid-policy and guideline development O Dewidar, BA Kawala, A Antequera, AC Tricco, D Tovey, S Straus, ... Journal of Clinical Epidemiology 150, 142-153, 2022 | 14 | 2022 |
| The antibiotic subscription model: fostering innovation or repackaging old drugs? RE Glover, AC Singer, AP Roberts, C Kirchhelle The Lancet Microbe 4 (1), e2-e3, 2023 | 12 | 2023 |
| Resources supporting trustworthy, rapid and equitable evidence synthesis and guideline development: results from the COVID-19 evidence network to support decision-making (COVID … M McCaul, D Tovey, T Young, V Welch, O Dewidar, M Goetghebeur, ... Journal of clinical epidemiology 151, 88-95, 2022 | 12 | 2022 |
| Temporal Changes in Ebola Transmission in Sierra Leone and Implications for Control Requirements: A Real-time Modelling Study. PLoS Curr [en línea]. 2015 Feb.[citado 11 Ago 2020] A Camacho, A Kucharski, Y Aki-Sawyerr, MA White, S Flasche, ... | 11 | |
| How pharmaceutical and diagnostic stakeholders construct policy solutions to a public health ¡crisis¢: an analysis of submissions to a United Kingdom House of Commons inquiry … RE Glover, MP Petticrew, NB Mays, C Thompson Critical Public Health, 1-10, 2022 | 10* | 2022 |
| Sankey diagrams can clarify ¡evidence attrition¢: A systematic review and meta-analysis of the effectiveness of rapid diagnostic tests for antimicrobial resistance RE Glover, M Al-Haboubi, MP Petticrew, E Eastmure, SJ Peacock, N Mays Journal of clinical epidemiology 144, 173-184, 2022 | 8* | 2022 |
| NIMble innovation—a networked model for public antibiotic trials RE Glover, AC Singer, AP Roberts, C Kirchhelle The Lancet Microbe 2 (11), e637-e644, 2021 | 8 | 2021 |
| Antimicrobial resistance at the G7 RE Glover, GM Knight, CIR Chandler bmj 373, 2021 | 8 | 2021 |
| Sale of UK¢s Vaccine Manufacturing and Innovation Centre RE Glover, AP Roberts, AC Singer, C Kirchhelle bmj 376, 2022 | 6 | 2022 |
| Have we reached “peak neoliberalism” in the UK¢s covid-19 response? RE Glover, N Maani | 6 | 2021 |
| The Commercial Determinants of Health and Evidence Synthesis (CODES): methodological guidance for systematic reviews and other evidence syntheses M Petticrew, RE Glover, J Volmink, L Blanchard, É Cott, C Knai, N Maani, ... Systematic Reviews 12 (1), 165, 2023 | 4 | 2023 |
